Advances in the Treatment of Ovarian Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 8909
Special Issue Editor
Special Issue Information
Dear Colleagues,
Ovarian cancer remains the deadliest gynecologic cancer in the United States, with more than 12,000 estimated deaths expected in 2022. The cure rate has not changed in over 50 years, and the majority of ovarian cancer patients are diagnosed at an advanced stage, with a median overall survival of <5 years. While incidence is gradually declining, prevalence is increasing, in part due to advances in treatment and maintenance strategies, including PARP inhibitors and antiangiogenic agents. Biomarkers, including BRCA and homologous recombination deficiency, play an important role in choosing maintenance therapy and will likely help to guide therapies with the development of antibody drug conjugates. Platinum-resistant ovarian cancer remains an area of high unmet need, where novel strategies are needed to improve outcomes. Low-grade serous ovarian cancer is relatively chemoresistant, so targeted therapies are being developed.
In this Special Issue, we wish to collect original research and review articles addressing all innovations dedicated to ovarian cancer treatment, including PARP inhibitors, antibody drug conjugates, immunotherapy, HIPEC, rate tumor type treatment (e.g., low grade serous, clear cell, mucinous), screening, role of secondary debulking, maintenance strategies post PARPi, and novel therapeutic combinations.
Dr. Debra L. Richardson
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PARP inhibitors
- antibody drug conjugates
- HIPEC
- immunotherapy
- screening
- secondary debulking
- ovarian cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.